Corgenix and Viral Hemorrhagic Fever Consortium Release New Findings from Sierra Leone Lassa Virus Program

November 14, 2012

Science presented at American Society of Tropical Medicine and Hygiene conference helps combat deadly viral hemorrhagic fevers, bioterrorism

ATLANTA AND DENVER – November 14, 2012 – Corgenix Medical Corporation (OTC BB:

CONX.OB), a worldwide developer and marketer of diagnostic test kits and the Viral Hemorrhagic Fever Consortium (VHFC) released new scientific data resulting from the consortium’s ongoing studies at the Kenema Government Hospital in Kenema, Sierra Leone. 

The results, presented this week at the 61st Annual Meeting of The American Society of Tropical Medicine and Hygiene (ASTMH) held in Atlanta, demonstrated that ELISA diagnostics tests are capable of diagnosing Lassa Fever viruses. 

The poster abstract Fevers of unknown origin in a cohort of patients presenting to Kenema Government Hospital, Sierra Leone, suspected of Lassa fever infection was presented by lead author and Corgenix Medical Program Director of Infectious Diseases Matt Boisen. The abstract demonstrated that Lassa fever (LF) assays, such as those being developed by the consortium, can help distinguish patients with LF from those with other illnesses. The LF assay used in the abstract provided the only clear method of differentiating LF patients from those with non-Lassa fevers of unknown origin (FUO).

The second abstract, Demographic and clinical risk factors for Lassa fever in Sierra Leone, found that patients who tested positive forthe Lassa Virus antigen using the consortium’s LF assay were more likely to have exhibited the most common LF symptoms compared to patients with other diseases. 

“This research provides the first detailed examination of Lassa fever epidemiology in post-conflict Sierra Leone. Through the work of the VHFC, we also find that the availability of good diagnostics and clinical treatment can transform hospitals into sentinel sites, generating samples that can illuminate the spectrum of infectious diseases that continue to claim millions of lives each year across Africa,” said Robert F. Garry, Ph.D., principal investigator for the VHFC. 

“The results released this week at the ASTMH meeting demonstrate the significant progress made over the past few years by consortium scientists in expanding the knowledge base of viral  hemorrhagic fevers,” said Douglass Simpson, President and CEO of Corgenix. “This is part of Corgenix’ corporate strategy to develop and commercialize testing platforms to identify these deadly viruses. We are continuing to advance several novel diagnostic products, which are already being commercialized in West Africa, and which we expect will be CE Marked and filed with the U.S. Food and Drug Administration (FDA) to make them available globally to address important bioterrorism concerns.”

Founded in 1903,The American Society of Tropical Medicine and Hygiene is a worldwide organization of scientists, clinicians and program professionals whose mission is to promote global health through the prevention and control of infectious and other diseases that disproportionately afflict the global poor. Research, health care and education are the central activities of ASTMH members, whose work bridges basic laboratory research to international field work and clinics to countrywide programs. More information is available at 

About the Viral Hemorrhagic Fever Consortium

The Consortium is a collaboration between Tulane University, Scripps Research Institute, Broad Institute, Harvard University, University of California at San Diego, University of Texas Medical Branch, Autoimmune Technologies LLC, Corgenix Medical Corporation, Kenema Government Hospital (Sierra Leone),Irrua Specialist Teaching Hospital (Nigeria) and various other partners in West Africa. The Viral Hemorrhagic Fever Consortium was established as a result of a contract awarded to Tulane University by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institute of Health (NIH). This contract was awarded for Tulane’s ongoing efforts to treat and prevent Lassa fever, a disease that threatens hundreds of thousands of lives annually in West Africa and is classified as a potential bioterrorism threat. More information is available at 

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at

Company Contact:

Corgenix Medical Corp.

William Critchfield, Senior VP Operations and Finance and CFO
Phone (303) 453-8903

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President,
Public Relations Supervisor
Phone: 303-623-1190 x 230